The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Daniel R. Budman

Section of Experimental Therapeutics

Don Monti Division of Oncology

Monter Cancer Center

North Shore Univ. Hospital - NYU

USA

[email]@nshs.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Section of Experimental Therapeutics, Don Monti Division of Oncology, Monter Cancer Center, North Shore Univ. Hospital - NYU, USA. 2006 - 2011
  • Department of Medicine, North Shore University Hospital, New York University Medical College, Manhasset 11030, USA. 1998 - 2004
  • Division of Medical Oncology, New York University, Medical College, North Shore University Hospital, USA. 2002
  • Cancer and Leukemia Group B, Chicago, USA. 1997

References

  1. The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. Budman, D.R., Tai, J., Calabro, A., John, V. Invest. New. Drugs (2011) [Pubmed]
  2. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Budman, D.R., Tai, J., Calabro, A. Breast Cancer Res. Treat. (2007) [Pubmed]
  3. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Budman, D.R., Soong, R., Calabro, A., Tai, J., Diasio, R. Anticancer. Drugs (2006) [Pubmed]
  4. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Budman, D.R., Calabro, A. Oncology (2006) [Pubmed]
  5. Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. Budman, D.R., Calabro, A. Anticancer. Drugs (2004) [Pubmed]
  6. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Budman, D.R., Calabro, A. Breast Cancer Res. Treat. (2002) [Pubmed]
  7. New directions with capecitabine combinations in advanced breast cancer. Budman, D.R. Oncology (Williston Park, N.Y.) (2002) [Pubmed]
  8. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Budman, D.R., Calabro, A., Kreis, W. Anticancer. Drugs (2002) [Pubmed]
  9. The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression. Budman, D.R. Cancer Invest. (2002) [Pubmed]
  10. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Budman, D.R., Johnson, R., Barile, B., Bowsher, R.R., Vinciguerra, V., Allen, S.L., Kolitz, J., Ernest, C.S., Kreis, W., Zervos, P., Walling, J. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  11. Capecitabine. Budman, D.R. Invest. New. Drugs (2000) [Pubmed]
  12. A phase I study of sequential vinorelbine followed by paclitaxel. Budman, D.R., Weiselberg, L., O'Mara, V., Buchbinder, A., Lichtman, S.M., Donahue, L., Adams, L.M. Ann. Oncol. (1999) [Pubmed]
  13. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. Budman, D.R., Meropol, N.J., Reigner, B., Creaven, P.J., Lichtman, S.M., Berghorn, E., Behr, J., Gordon, R.J., Osterwalder, B., Griffin, T. J. Clin. Oncol. (1998) [Pubmed]
  14. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., Ferree, C.R., Muss, H.B., Green, M.R., Norton, L., Frei, E. J. Natl. Cancer Inst. (1998) [Pubmed]
  15. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B. Budman, D.R., Petroni, G.R., Johnson, J.L., Cooper, M.R., Schlossman, D.M., Barcos, M., Peterson, B.A. J. Clin. Oncol. (1997) [Pubmed]
 
WikiGenes - Universities